Adcock Ingram eyes new products as it battles rising costs
20 February 2020 - 08:24
bykarl gernetzky
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
JSE-listed local pharmaceutical manufacturer Adcock Ingram, a subsidiary of the Bidvest group, said on Thursday a heavy focus on cost control ensured it eked out profit growth in its half-year to end-December, though it was battling rising costs.
Utility costs rose 11.4% during its half-year and labour costs 7%, with the company saying this was offset by an advantageous sales mix and “excellent” output at its manufacturing facilities.
Trading profit rose 1% to R490m, with the company declaring an interim dividend of 100c, unchanged from the prior comparative period.
The SA economic climate and consumer spending was still a concern, and margins were expected to be under pressure from cost increases, particularly labour, transport and utilities, said CEO Andrew Hall.
“To attempt to protect margins, the group has placed a heightened focus on driving productivity in the factories, continued strict cost control and expanding the group’s product portfolio, particularly in less regulated product classes,” he said.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Adcock Ingram eyes new products as it battles rising costs
JSE-listed local pharmaceutical manufacturer Adcock Ingram, a subsidiary of the Bidvest group, said on Thursday a heavy focus on cost control ensured it eked out profit growth in its half-year to end-December, though it was battling rising costs.
Utility costs rose 11.4% during its half-year and labour costs 7%, with the company saying this was offset by an advantageous sales mix and “excellent” output at its manufacturing facilities.
Trading profit rose 1% to R490m, with the company declaring an interim dividend of 100c, unchanged from the prior comparative period.
The SA economic climate and consumer spending was still a concern, and margins were expected to be under pressure from cost increases, particularly labour, transport and utilities, said CEO Andrew Hall.
“To attempt to protect margins, the group has placed a heightened focus on driving productivity in the factories, continued strict cost control and expanding the group’s product portfolio, particularly in less regulated product classes,” he said.
gernetzkyk@businesslive.co.za
Adcock looks to AIDS tender to boost Wadeville plant
Adcock Ingram and Aspen Pharmacare win share of government AIDS drug contract
Adcock Ingram shares rise after securing state HIV drug contract
Bidvest bemoans lack of finance for BEE deal
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Stockpiles protect drug makers from coronavirus disruption
Four drugmakers withdraw heartburn medicine in SA over safety concerns
Adcock shares rise as prescription medicine boosts sales
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.